Why the study?
Does thapsigargin rescue the surface expression of trafficking defective LQT2 mutations without blocking HERG current in HEK293 cells?
Population
Human embryonic kidney 293 cell lines stably expressing WT HERG and the trafficking defective LQT2 mutations…
Comparison
Thapsigargin (1 μm) vs E4031, other SERCA inhibitors, or vehicle
Design
Preclinical
Authors
Loading...
Hypothesis-generating for non-blocking rescue in select LQT2 mutations; leaves open translation beyond HEK293 cells.
Does thapsigargin rescue the surface expression of trafficking defective LQT2 mutations without blocking HERG current in HEK293 cells?
Thapsigargin selectively rescues the surface expression of specific trafficking-defective LQT2 mutations (G601S and F805C) without blocking the HERG channel current, demonstrating proof-of-concept for non-blocking pharmacological rescue.
Delisle et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: